Approches actuelles au traitement du zona: Aspects controversés du traitement du zona

Autor Bissonnette, R., Leclerc, G.
Vydáno 1992

Retinoids cause apoptosis in pancreatic cancer cells via activation of RAR-γ and altered expression of Bcl-2/Bax

Autor Pettersson, F, Dalgleish, A G, Bissonnette, R P, Colston, K W
Vydáno 2002

A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis

Autor Ports, WC, Khan, S, Lan, S, Lamba, M, Bolduc, C, Bissonnette, R, Papp, K
Vydáno 2013

Immunoregulatory activity of a T-cell receptor alpha chain demonstrated by in vitro transcription and translation.

Autor Onda, T, Brunner, T, Messier, H, Bissonnette, R, Echeverri, F, Baier, G, Fotedar, A, Green, D R
Vydáno 1995

9-cis retinoic acid inhibition of activation-induced apoptosis is mediated via regulation of fas ligand and requires retinoic acid receptor and retinoid X receptor activation.

Autor Bissonnette, R P, Brunner, T, Lazarchik, S B, Yoo, N J, Boehm, M F, Green, D R, Heyman, R A
Vydáno 1995

The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice

Autor Li, Y, Zhang, Y, Hill, J, Kim, H-T, Shen, Q, Bissonnette, R P, Lamph, W W, Brown, P H
Vydáno 2008

Immunoregulatory activity of the T-cell receptor alpha chain demonstrated by retroviral gene transfer.

Autor Green, D R, Bissonnette, R, Zheng, H G, Onda, T, Echeverri, F, Mogil, R J, Steele, J K, Voralia, M, Fotedar, A
Vydáno 1991

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients...

Autor Papp, KA, Barber, K, Bissonnette, R, Bourcier, M, Lynde, CW, Poulin, Y, Shelton, J, Toole, J, Vieira, A, Poulin-Costello, M
Vydáno v J Eur Acad Dermatol Venereol (2015)

Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey‐based position statement

Autor Leshem, Y.A., Bissonnette, R., Paul, C., Silverberg, J.I., Irvine, A.D., Paller, A.S., Cork, M.J., Guttman‐Yassky, E.
Vydáno v J Eur Acad Dermatol Venereol (2019)

Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate‐to‐severe psoriasis through 5 years of treatment (SCULPTURE Extension Stu...

Autor Bissonnette, R., Luger, T., Thaçi, D., Toth, D., Lacombe, A., Xia, S., Mazur, R., Patekar, M., Charef, P., Milutinovic, M., Leonardi, C., Mrowietz, U.
Vydáno v J Eur Acad Dermatol Venereol (2018)

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

Autor Papp, K.A., Barber, K., Bissonnette, R., Bourcier, M., Lynde, C.W., Poulin, Y., Shelton, J., Garces, K., Toole, J., Poulin‐Costello, M.
Vydáno v J Eur Acad Dermatol Venereol (2015)

The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate‐to‐severe atopic dermati...

Autor Bissonnette, R., Maari, C., Forman, S., Bhatia, N., Lee, M., Fowler, J., Tyring, S., Pariser, D., Sofen, H., Dhawan, S., Zook, M., Zammit, D.J., Usansky, H., Denis, L., Rao, N., Song, T., Pavel, A.B., Guttman‐Yassky, E.
Vydáno v Br J Dermatol (2019)